Skip to main content

Advertisement

SpringerLink
Log in

Duration of posaconazole therapy for Aspergillus fumigatus osteomyelitis dictated by serial monitoring of 1,3-beta-D glucan

  • Case Report
  • Published:
Infection Aims and scope Submit manuscript

Abstract

Here, we present a case of an immunocompetent 37-year old male who developed Aspergillus fumigatus osteomyelitis 16 years after extensive chest wall reconstructive surgery for Ewing sarcoma. His treatment course was complicated by a severe adverse drug reaction to voriconazole, requiring the use of oral posaconazole therapy. Serum 1,3-beta-D glucan assay was utilized to dictate the duration of posaconazole therapy. The patient successfully completed 9 months of oral posaconazole therapy and has not had clinical recurrence for 9 months off antifungal therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Fang W, et al. Microbe profile: aspergillus fumigatus: a saprotrophic and opportunistic fungal pathogen. Microbiology. 2018;164:1009–111.

    Article  CAS  Google Scholar 

  2. Vinas F, et al. Spinal aspergillus osteomyelitis. Clin Infect Dis. 1999;28:1223–9.

    Article  CAS  Google Scholar 

  3. Gamaletsou M, et al. Aspergillus osteomyelitis: epidemiology, clinical manifestations, management, and outcome. J Infect. 2014;68:478–93.

    Article  Google Scholar 

  4. Patterson T, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 Update by the infectious diseases society of America. Clin Infect Dis. 2016;63:e1–e60.

    Article  Google Scholar 

  5. Nicholson S, et al. Aspergillus osteomyelitis of the skull. J Craniofacial Surg. 2016;27:e504–e506506.

    Article  Google Scholar 

  6. Noxafil package insert. Merck & Co, Inc. NJ: Whitehouse Station; 2014.

    Google Scholar 

  7. Lodge B, et al. Aspergillus fumigatus empyema, arthritis, and calcaneal osteomyelitis in a lung transplant patient successfully treated with posaconazole. J Clin Microbiol. 2004;42:1376–8.

    Article  Google Scholar 

  8. Hodiamont C, et al. Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery. Med Mycol. 2009;47:217–20.

    Article  CAS  Google Scholar 

  9. Mandell G, et al. Principles and practice of infectious diseases. 7th ed. Philadelphia: Elsevier inc; 2010.

    Google Scholar 

  10. Lash B, et al. Cross-reactivity between voriconazole, fluconazole and itraconazole. J Clin Pharm Ther. 2016;41:566–7.

    Article  Google Scholar 

  11. Morales M, et al. Graded isavuconazole introduction in a patient with voriconazole allergy. Transpl Infect Dis. 2017;19:e12772. https://doi.org/10.1111/tid.12772.

    Article  Google Scholar 

  12. Slomaka M, et al. A rare case of Blastomyces dermatitidis brain abscess in an immunocompetent host. Med Mycology Case Rep. 2020;28:8–11.

    Article  Google Scholar 

  13. Lamoth F, et al. β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis. 2012;54:633–43.

    Article  Google Scholar 

  14. Singh S, et al. Evaluation of biomarkers: Galactomannan and 1,3-beta-D-glucan assay for the diagnosis of invasive fungal infections in immunocompromised patients from a tertiary care centre. Indian J Med Microbiol. 2018;36:557–63.

    Article  Google Scholar 

  15. Ellis M, et al. Assessment of the clinical utility of serial beta-D-glucan concentrations in patients with persistent neutropenic fever. J Med Microbiol. 2008;57:287–95.

    Article  CAS  Google Scholar 

  16. Desoubeaux G, et al. Combination of β-(1, 3)-D-glucan testing in serum and qPCR in nasopharyngeal aspirate for facilitated diagnosis of Pneumocystis jirovecii pneumonia. Mycoses. 2019;62:1015–22.

    Article  CAS  Google Scholar 

  17. Pini P, et al. Prognostic potential of the panfungal marker (1 → 3)-β-D-Glucan in invasive mycoses patients. Mycopathologia. 2019;184:147–50.

    Article  CAS  Google Scholar 

  18. Martson A, et al. Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations. Mycoses. 2019;62:698–705.

    Article  Google Scholar 

Download references

Acknowledgements

We are grateful for the assistance provided by the University of Maryland Medical Center microbiology laboratory.

Funding

None.

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, University of Maryland School of Medicine, 725 west Lombard Street, Baltimore, MD, 21201, USA

    James B. Doub & Poonam Mathur

Authors
  1. James B. Doub
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Poonam Mathur
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James B. Doub.

Ethics declarations

Conflict of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Doub, J.B., Mathur, P. Duration of posaconazole therapy for Aspergillus fumigatus osteomyelitis dictated by serial monitoring of 1,3-beta-D glucan. Infection 48, 959–963 (2020). https://doi.org/10.1007/s15010-020-01489-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15010-020-01489-2

Keywords

Search

Navigation